Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 6/2003

01-05-2003 | Review Article

Deposition and Effects of Inhaled Corticosteroids

Author: Dr Stephen P. Newman

Published in: Clinical Pharmacokinetics | Issue 6/2003

Login to get access

Abstract

Inhaled corticosteroids are now recommended as maintenance therapy for all but the mildest cases of asthma, and may be delivered by a variety of devices and formulations. Drug delivery may be assessed by both in vitro and in vivo methods. Although drug deposition in the lungs is expected to predict clinical response, this relationship is often masked by the flat nature of corticosteroid dose-response curves. The effects of inhaled corticosteroids depend not only upon the pharmacology of the drug being administered, but also upon its delivery system, with more efficient devices not only improving therapeutic effect but also potentially increasing systemic adverse effects. Modern delivery systems that enhance drug targeting to the lungs make it possible to use lower dosages of inhaled corticosteroid, such that the clinical response is maintained but systemic exposure reduced.
Footnotes
1
Use of tradenames is for product identification only and does not imply endorsement
 
Literature
1.
Dolovich MB. Physical principles underlying aerosol therapy. J Aerosol Med 1989; 2: 171–85CrossRef
2.
British Asthma Guildelines Coordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1–S24CrossRef
3.
Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1–S53PubMed
4.
Howarth PH. What is the nature of asthma and where are the therapeutic targets?. Respir Med 1997; 91 Suppl. A: 2–8PubMedCrossRef
5.
Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 Suppl. A: 22–8PubMedCrossRef
6.
Thorsson L, Edsbäcker S, Källén A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529–38PubMedCrossRef
7.
Bousquet J, D’Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: 808–16PubMedCrossRef
8.
Derendorf H, Daley-Yates P, Pierre LN, et al. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001; 17: 157–8PubMedCrossRef
9.
Newman SP. Devices for inhaling medications. In: Clark TJH, Lee T, Godfrey S, Thomson NC, editors. Asthma. 4th ed. London: Edward Arnold Limited, 2000: 329–54
10.
Partridge MR, Woodcock AA, Sheffer AL, et al. Chlorofluorocarbon-free inhalers: are we ready for the change?. Eur Respir J 1998; 11: 1006–8PubMedCrossRef
11.
Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996; 9: 55–70PubMedCrossRef
12.
Lipworth BJ. Targets for inhaled treatment. Respir Med 2000; 94 Suppl. D: S13–6PubMed
13.
Poulter LW. Central inflammation is more important than peripheral inflammation. Respir Med 1997; 91 Suppl. A: 9–10
14.
Hamid QA. Peripheral inflammation is more important than central inflammation. Respir Med 1997; 91 Suppl. A: 11–2PubMedCrossRef
15.
Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289–99PubMedCrossRef
16.
Ganderton D, Byron P. Harmonising inhaler testing across the Pharmacopeias. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 283–92
17.
Hindle M, Byron P. Impaction and impingement techniques for powder inhalers: comparisons, problems and validation. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 263–72
18.
Wright P. Next generation impactor: European update. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 479–81
19.
Hallworth GW. Particle size analysis of therapeutic aerosols. In: Morén F, Dolovich MB, Newhouse MT, et al., editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 351–74
20.
Kenyon CJ, Dewsbury NJ, Newman SP. Differences in aerodynamic particle size distribution of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacer. Thorax 1995; 50: 846–50PubMedCrossRef
21.
Newman SP, Talaee N, Clarke SW. Salbutamol aerosol delivery with the Rondo spacer. Acta Ther 1991; 17: 49–58
22.
Zanen P, Lammers JWJ. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995; 48: 179–84PubMedCrossRef
23.
Kamada AK, Szefler SJ. How should inhaled glucocorticoids be compared?. J Allergy Clin Immunol 1997; 99: 735–7PubMedCrossRef
24.
Pauwels R, Newman SP, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered dose inhalers. Eur Respir J 1997; 10: 2127–38PubMedCrossRef
25.
Barnes PJ. Corticosteroids: mode of action and place in management. In: Clark TJH, Lee T, Godfrey S, et al., editors. Asthma. 4th ed. London: Edward Arnold Limited, 2000: 304–28
26.
Engel T, Heinig JH, Mailing H-J, et al. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 1989; 44: 220–5PubMedCrossRef
27.
O’Callaghan C, Lynch J, Cant M, et al. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation and avoiding multiple actuations of drug. Thorax 1993; 48: 603–6PubMedCrossRef
28.
Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130–3PubMedCrossRef
29.
Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476–82PubMedCrossRef
30.
Derendorf H, Hochhaus G, Möllman H. Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med 2001; 14 Suppl. 1: S9–S17PubMedCrossRef
31.
Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6: 367–75PubMedCrossRef
32.
Lipworth BJ. The comparative safety/efficacy of HFA-BDP. Respir Med 2000; 94 Suppl. D: S21–6PubMed
33.
Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105–10PubMedCrossRef
34.
Davies DS. Pharmacokinetics of inhaled substances. Postgrad Med J 1975; 51 Suppl. 7: 69–75PubMed
35.
Auty RM, Brown K, Neale MG, et al. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br J Dis Chest 1987; 81: 371–80PubMedCrossRef
36.
Falcoz C, Oliver R, McDowell JE, et al. Bioavailability of orally administered micronized fluticasone propionate. Clin Pharmacokinet 2000; 39 Suppl. 1: 9–15PubMedCrossRef
37.
Borgström L, Derom E, Stahl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636–40PubMed
38.
Borgström L, Newman S, Weisz A, et al. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion method. J Pharm Sci 1992; 81: 753–5PubMedCrossRef
39.
Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J 1994; 7: 1839–44PubMedCrossRef
40.
Thorsson L, Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998; 12: 1340–5PubMedCrossRef
41.
Olsson B, Borgström L, Asking L, et al. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove (IL): Interpharm Press, 1996: 273–81
42.
Newnham DM, McDevitt DG, Lipworth BJ. Comparison of the extrapulmonary beta-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36: 445–50PubMedCrossRef
43.
Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311–5PubMed
44.
Lipworth BJ, Jackson CM. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999; 48: 866–8PubMedCrossRef
45.
Chrystyn H, Corlett SA, Silkstone V. Lung bioavailability of generic and innovator salbutamol MDIs [letter]. Thorax 1996; 51: 658PubMedCrossRef
46.
Lipworth BJ, Clark DJ. Lung bioavailability of generic and innovator salbutamol MDIs [letter]. Thorax 1996; 51: 658CrossRef
47.
Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247–9PubMedCrossRef
48.
Chrystyn H, Allen MB, Corlett SA, et al. Simultaneous measurement of pharmacodynamic and pharmacokinetic parameters which can be used to evaluate the influence of inhaled salbutamol [abstract]. Am J Respir Crit Care Med 1998; 157: A636
49.
Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Respir Med 1999; 93: 123–33PubMedCrossRef
50.
Dolovich MB. Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med 2001; 14 Suppl. 1: S35–44PubMedCrossRef
51.
Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001; 14: 147–53PubMedCrossRef
52.
Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled Pharmaceuticals. Curr Pharm Des 2000; 6: 1631–51PubMedCrossRef
53.
Newman SP. Scintigraphic assessment of pulmonary delivery systems. Pharm Tech 1998 Jun; 22: 78–94
54.
Chan H-K. Use of single photon emission computed tomography in aerosol studies. J Aerosol Med 1993; 6: 23–36PubMedCrossRef
55.
Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur Respir J 1995; 8: 1001–17PubMed
56.
Phipps PR, Gonda I, Bailey DL, et al. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis 1989; 139: 1516–23PubMed
57.
Dolovich M, Hahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Raleigh (NC): Serentec Press, 2000: 215–30
58.
Yanai M, Hatazawa J, Ojima F, et al. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 11: 1342–8PubMedCrossRef
59.
Berridge MS, Lee Z, Heald DL. Pulmonary distribution and kinetics of inhaled 11C triamcinolone acetonide. J Nucl Med 2000; 41: 1603–11PubMed
60.
Conway JH, Holgate ST. Targeting therapy to inflamed airways in asthma. J Aerosol Med 1994; 7: 161–5CrossRef
61.
Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medications. Chest 1998; 113: 957–63PubMedCrossRef
62.
Borgström L, Bondesson E, Morén F, et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69–73PubMedCrossRef
63.
Kenyon CJ, Thorsson L, Borgström L, et al. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 1998; 11: 606–10PubMed
64.
Thorsson L, Kenyon CJ, Newman SP, et al. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm 1998; 168: 119–27CrossRef
65.
Pitcairn GR, Lankinen T, Seppälä O-P, et al. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient’s inspiratory effort. J Aerosol Med 2000; 13: 97–104PubMedCrossRef
66.
Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000; 16: 178–83PubMedCrossRef
67.
Richards JC, Hirst PH, Pitcairn GR, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14: 197–208PubMedCrossRef
68.
Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 2001; 95: 720–7PubMedCrossRef
69.
Newman SP, Pitcairn GR, Adkin DA, et al. Comparison of beclomethasone dipropionate delivery by Easyhaler dry powder inhaler and pMDI plus large volume spacer. J Aerosol Med 2001; 14: 217–25PubMedCrossRef
70.
Warren SJ, Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (Clickhaler), a conventional metered dose inhaler and MDI plus spacer. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove (IL): Interpharm Press, 1998: 453–55
71.
Conway JH, Walker P, Fleming JS, et al. Three-dimensional description of the deposition of inhaled terbutaline sulphate administered via Turbuhaler. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Raleigh (NC): Serentec Press, 2000: 607–9
72.
Newman SP, Steed K, Hooper G, et al. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler. Pharm Res 1995; 12: 231–6PubMedCrossRef
73.
Snell NJC. Equivalence testing: the special case of inhaled medications. Int J Pharm Med 1998; 12: 245–6
74.
Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo?. J Aerosol Med 1998; 11 Suppl. 1: S97–S104PubMed
75.
Farr SJ, Warren SJ, Lloyd P, et al. Comparison of in vitro and in vivo efficiencies of a novel unit-dose aerosol generator and a pressurized metered dose inhaler. Int J Pharm 2000; 198: 63–70PubMedCrossRef
76.
Borgström L. The pharmacokinetics of inhaled hydrofluoroalkane formulations. J Allergy Clin Immunol 1999; 104: S246–9PubMedCrossRef
77.
Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?. Int J Pharm 2000; 208: 49–60PubMedCrossRef
78.
79.
Dolovich MB, Ruffin R, Corr D, et al. Clinical evaluation of a new demand-inhalation MDI aerosol delivery device. Chest 1983; 84: 36–41PubMedCrossRef
80.
Melchor R, Biddiscombe MF, Mak VHF, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airways obstruction. Thorax 1993; 48: 506–11PubMedCrossRef
81.
Falcoz C, Mackie AE, Horton J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in asthmatic patients [abstract]. Br J Clin Pharmacol 1997; 43: 541P–2P
82.
Mackie AE, Falcoz C, McDowall JE, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in healthy subjects [abstract]. Br J Clin Pharmacol 1997; 43: 540P–1P
83.
Daley-Yates PT, Tournant J, Kunka R. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 2000; 39 Suppl. 1: 39–45PubMedCrossRef
84.
Lipworth BJ, Clark DJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 1997; 52: 1036–9PubMedCrossRef
85.
Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother 1996; 6: 273–99CrossRef
86.
Mackie AE, McDowell JE, Ventresca P, et al. Systemic exposure to fluticasone propionate administered via metered dose inhaler containing chlorofluorocarbon or hydrofluorocarbon propellant. Clin Pharmacokinet 2000; 39 Suppl. 1: 17–22PubMedCrossRef
87.
Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001; 14 Suppl. 1: S19–26PubMedCrossRef
88.
89.
Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12: 1346–53PubMedCrossRef
90.
Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998; 92 Suppl. A: 9–15PubMedCrossRef
91.
Busse W, Colice G, Hannon S. CFC-BDP requires 2.6 times the dose to achieve equivalent improvement in FEV1 as HFA-BDP [abstract]. Am J Respir Crit Care Med 1998; 157: A405
92.
Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215–22PubMedCrossRef
93.
Davies RJ, Stampone P, O’Connor BJ. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 Suppl. A: 23–31PubMedCrossRef
94.
Muir J-J. An overview of the clinical efficacy of HFA-BDP in asthma. Respir Med 2000; 94 Suppl. D: S17–20PubMed
95.
Reichel W, Dahl R, Ringdal N, et al. Extrafine beclomethasone dipropionate breath-actuated inhaler (400µg/day) versus budesonide dry powder inhaler (800µg/day) in asthma. Int J Clin Pract 2001; 55: 100–6PubMed
96.
Milanowski J, Qualtrough J, Perrin VL. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA-134a) is equivalent to BDP-CFC for the treatment of asthma. Respir Med 1999; 93: 245–51PubMedCrossRef
97.
98.
99.
100.
Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87: 405–11PubMedCrossRef
101.
102.
Clark DJ, Lipworth BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55–8PubMedCrossRef
103.
Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax 1993; 48: 233–8PubMedCrossRef
104.
Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1–S26PubMed
105.
Hämäläinen KM, Granander M, Toivanen P, et al. Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers. Respir Med 2001; 95: 863–9PubMedCrossRef
106.
Thorsson L. Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids. J Aerosol Med 1995; 8 Suppl. 3: S29–37PubMedCrossRef
107.
Thompson PJ, Davies RJ, Young WF, et al. Safety of hydroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 1998; 92 Suppl. A: 33–9PubMedCrossRef
108.
Selroos O. Bronchial asthma, chronic bronchitis and pulmonary parenchymal diseases. In: Morén F, Dolovich MB, Newhouse MT, Newman SP, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier, 1993: 261–89
109.
Toogood JH, Baskerville J, Jennings B, et al. Use of spacers to facilitate inhaled corticosteroid treatment in asthma. Am Rev Respir Dis 1984; 129: 723–9PubMed
110.
Selroos O, Halme M. Effect of a volumetric spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46: 891–4PubMedCrossRef
Metadata
Title
Deposition and Effects of Inhaled Corticosteroids
Author
Dr Stephen P. Newman
Publication date
01-05-2003
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 6/2003
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342060-00003

Other articles of this Issue 6/2003

Clinical Pharmacokinetics 6/2003 Go to the issue

Original Research Article

Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin in Patients with Early-Onset Ventilator-Associated Pneumonia

Review Article

Pharmacokinetics of the Dietary Supplement Creatine

Review Article

Pharmacokinetics of Rofecoxib

Original Research Article

Pharmacokinetic and Pharmacodynamic Studies of SK-896, a New Human Motilin Analogue, in Healthy Male Volunteers

Leading Article

Intranasal Diamorphine as an Alternative to Intramuscular Morphine

Original Research Article

Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population